One significant finding is from the SELECT trial, which showed that long-term use of semaglutide in individuals with obesity but without diabetes led to a 20% reduction in major cardiovascular events and an average weight loss of 9.4%
For example, the DURATION-8 study demonstrated that mean bodyweight loss with the combination of exenatide (GLP1-RA, which suppresses appetite) once weekly and dapagliflozin (SGLT2 inhibitor) once daily in patients with T2D was greater than that with the monotherapies alone [17]
Subcutaneous injection sites include abdomen (5 cm from umbilicus), anterior thigh, or posterior upper arm, rotated weekly to prevent lipohypertrophy
In 1993 Holst and his colleagues had noted GLP-1 receptors in the vagal nerve which runs from the gut to the brain
You inject once weekly, and the medication maintains therapeutic effects throughout that full week
According to functional magnetic resonance imaging, anticipatory food reward the anticipated pleasure of eating certain meals is reduced when GLP- 1 R is activated [110, 111]